scholarly journals Serum Total SOD Activity and SOD1/2 Concentrations in Predicting All-Cause Mortality in Lung Cancer Patients

2021 ◽  
Vol 14 (11) ◽  
pp. 1067
Author(s):  
Katarzyna Beata Skórska ◽  
Sylwia Płaczkowska ◽  
Anna Prescha ◽  
Irena Porębska ◽  
Monika Kosacka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cox Regression ◽  
Clinical Stage ◽  
Redox Status ◽  
Sod Activity ◽  
Lung Cancer Patients ◽  
Prediction Of Mortality ◽  
All Cause Mortality ◽  
And Control

Background: Redox status disturbances are known during carcinogenesis and may have influence on patients’ survival. However, the prediction of mortality in lung cancer patients based on serum total SOD activity, and concentrations of its isoforms, has not been studied to date. This prospective cohort study has following aims: (1) to evaluate the disturbances in serum SOD activity and SOD1/2 concentrations; (2) to assess the implications of these alterations with regard to biochemical variables and clinical data, and (3) to investigate the association between serum SOD activity, SOD1/2 concentrations, and all-cause mortality in lung cancer patients. Methods: Serum total SOD activity and SOD1, SOD2, albumin, CRP, and ceruloplasmin concentrations were determined in lung cancer patients (n = 190) and control subjects (n = 52). Additionally, patients were characterized in terms of biochemical, clinical, and sociodemographic data. Multiple Cox regression models were used to estimate the association between all-cause death and SOD-related parameters. Results: All-cause mortality in lung cancer was positively associated with serum SOD1 and SOD2 concentrations. Clinical stage III and IV disease was the strongest predictor. The utility of the evaluated parameters in predicting overall survival was demonstrated only for SOD1. Conclusions: Serum SOD1 and SOD2 concentrations were shown to positively affect all-cause mortality in lung cancer patients, but SOD1 seems to be a better predictor than SOD2.

scholarly journals Serum and Whole Blood Cu and Zn Status in Predicting Mortality in Lung Cancer Patients

Nutrients ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 60
Author(s):  
Katarzyna Zabłocka-Słowińska ◽  
Anna Prescha ◽  
Sylwia Płaczkowska ◽  
Irena Porębska ◽  
Monika Kosacka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Whole Blood ◽  
Clinical Stage ◽  
Cox Proportional Hazards ◽  
Chronic Obstructive ◽  
Lung Cancer Patients ◽  
All Cause Mortality ◽  
Zn Status ◽  
Cu And Zn

Alterations in circulating Cu and Zn are negative predictors of survival in neoplastic patients and are known during lung cancer. However, no data on predicting mortality of lung cancer patients based on the level of these elements in the blood have been presented to date. The aims of this prospective cohort study were as follows: (i) To evaluate the disturbances in serum and whole blood Cu and Zn, (ii) to assess the relationships between serum and whole blood Cu and Zn status and clinical, sociodemographic, and nutritional data, and (iii) to investigate the association of Cu and Zn status with all-cause mortality in lung cancer. Naïve-treatment lung cancer patients (n = 167) were characterized in terms of sociodemographic, clinical, and anthropometric data and dietary intake and compared with sex-matched control subjects (n = 48). Whole blood and serum Cu and Zn status was determined by atomic absorption spectrometry. Cox proportional hazards models adjusted for multiple confounders/mediators were used to estimate the association between all-cause death and Cu and Zn status. Sex, cardiovascular disease, chronic obstructive pulmonary disease, clinical stage, and hemoglobin, platelet, and glucose concentrations significantly differentiated Cu and Zn status. All-cause mortality in lung cancer patients was positively associated with serum Cu levels, Cu:Zn ratio, and whole blood Zn levels. However, an advanced clinical stage of disease was the strongest predictor of all-cause mortality. Circulatory status of Cu and Zn might be included in routine clinical characteristics of patients with lung cancer patients as additional prognostic variables, but only after further more detail studies.

scholarly journals Diagnostic value of α-enolase expression and serum α-enolase autoantibody levels in lung cancer

2018 ◽  
Vol 44 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Lihong Zhang ◽  
Hongbin Wang ◽  
Xuejun Dong
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Diagnostic Value ◽  
Smoking History ◽  
Lung Cancer Patients ◽  
Pathological Classification ◽  
Cancer Tissues ◽  
Antibody Levels

ABSTRACT Objective: To investigate the diagnostic value of α-enolase (ENO1) and serum ENO1 autoantibody levels in lung cancer. Methods: Immunohistochemistry staining and ELISA were performed to detect ENO1 expression in lung tissue and serum ENO1 autoantibody levels, respectively. Results: The expression of ENO1 was higher in lung cancer tissues than in benign lung disease tissues (p < 0.001). The proportion of lung cancer samples expressing ENO1 was not significantly different among the various pathological classification groups. The proportion of samples expressing ENO1 was higher in lung cancer patients in stages I/II than in those in stages III/IV (χ2 = 5.445; p = 0.018). The expression of ENO1 in lung cancer tissues was not associated with age, gender, or smoking history. Serum ENO1 antibody levels were significantly higher in the lung cancer group than in the benign lung disease and control groups (p < 0.001). The differences among the pathological classification groups were not statistically significant. Serum ENO1 antibody levels were also in lung cancer patients in stages I/II than in those in stages III/IV (p < 0.01). Serum ENO1 antibody levels were not associated with age, gender, or smoking history in lung cancer patients. The ROC curve representing the diagnosis of lung cancer based on ENO1 antibody levels had an area under the curve of 0.806. Conclusions: Our results suggest that high levels of ENO1 are associated with the clinical stage of lung cancer and that ENO1 expression and its serum autoantibody levels show diagnostic value in lung cancer.

Protective effect of metformin in lung cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22063-e22063
Author(s):  
B. Gagnon ◽  
M. Roseman ◽  
G. Kasymjanova ◽  
N. MacDonald ◽  
H. Kreisman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cox Regression ◽  
Human Cell Lines ◽  
Community Based ◽  
Cox Regression Analysis ◽  
Lung Cancer Patients ◽  
The Past ◽  
Jewish General Hospital

e22063 Background: Over the past decade, dozens of studies have shown that metformin not only decreases mortality in diabetics, it also significantly reduces CRP and reduces the risks of cancer in rodent and human cell lines. We report on the survival of lung cancer patients concomitantly exposed to metformin in our community-based program. Methods: 850 patients undergoing treatment from a prospectively collected pulmonary oncology database of the SMBD-Jewish General Hospital over an 8-year period were analyzed. Pilot observational study of survival was performed using Cox regression model. The factors that were included in the model were age, gender, stage, histology and metformin use. Results: 850 patients (F: M=375:475; mean age of 66) were diagnosed since 2000 and followed in pulmonary oncology outpatient clinic for NSCLC. 523 (62%) of those patients were diagnosed with adenocarcinoma; 488 (57%) were stage IIIB with pleural effusion/IV. 79(9%) patients were receiving treatment with metformin for their comorbid type 2 diabetes. The Cox regression analysis demonstrated that age, gender, stage and use of metformin were significant prognostic factors for survival. The use of metformin is associated with a 37% (HR 1.37; CI 1.01–1.84) (p=0.039) increase in survival. Conclusions: Thus, the result obtained from our model suggests that use of metformin may be associated with better survival of lung cancer patients. As this is a pilot study, we will consider alternative explanations. No significant financial relationships to disclose.

scholarly journals The prognostic value of PET/CT in clinical stage I lung cancer patients: A propensity-match analysis.

2019 ◽  
Author(s):  
Bing-Yen Wang ◽  
Wei-Heng Hung ◽  
Jing-Yang Huang ◽  
Heng-Chung Chen ◽  
Ching-Hsiung Lin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Clinical Stage ◽  
Survival Rates ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Pet Ct ◽  
Stage I Lung Cancer

Abstract Introduction The application of PET/CT directly improved treatment choice and management in 25% of non-small cell lung cancer patients and 29% of small cell lung cancer patients. However, the long-term outcome of altering the management of these patients remains unclear. The aim of this study was to compare the 5-year overall survival rates of two groups of clinical stage I lung cancer patients: those who received PET/CT and those who did not.Methods Data were obtained from the Taiwan Society of Cancer Registry. There were 6,587 clinical stage I lung cancer patients analyzed between 2009 and 2014 in this retrospective study. We performed propensity matching to reduce the bias; it resulted in both groups having 2,649 patients. We measured the 1, 3, and 5-year survival rates of all clinical stage I lung cancer patients and the survival rates of pathological I, II and III lung cancer patients and compared the survival rates between clinical stage I lung cancer patients with PET/CT scans and patients without PET/CT scans.Results The 1, 3, and 5-year survival rates of all clinical stage I lung cancer patients are 97.2%, 88.2% and 79.0%, respectively. The 1, 3, and 5-year survival rates are 97.0%, 88.2% and 79.8% in the PET/CT group and 97.5%, 88.1% and 78.2% in the no PET/CT group; there was no statistical difference (p= 0.6528).Conclusion Although stage I lung cancer patients who received PET/CT had their management strategies modified and avoided any unnecessary thoracotomies, our data showed that there was no 5-year survival benefit for these patients.

scholarly journals Radiotherapy for Lung Cancer During the COVID Pandemic – A Narrative Review of Practical Recommendations

2021 ◽  
Vol 1 (1) ◽  
pp. 99-117
Author(s):  
Prasenjit Chatterjee ◽  
Jibak Bhattacharya ◽  
Tanmay Ghosh ◽  
Biplap Sarkar ◽  
Monica-Emilia Chirilă ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Negative Impact ◽  
Clinical Stage ◽  
Performance Status ◽  
Treatment Decision ◽  
Original Research ◽  
Curative Intent ◽  
Lung Cancer Patients ◽  
Pubmed Database

"Background: The coronavirus disease pandemic produced changes in the treatment approach of lung cancer patients. They represent a vulnerable population due to the negative impact of delays in diagnosis and treatment and also because of the impaired immune system. Radiation Therapy plays a crucial role in both curative and palliative settings, so finding the best approach for these patients in this context was attempted by many professionals. The aim of this study was to make a synthesis of the current published literature on this topic and summarize the recommendations. Material and methods: We searched the PubMed database for articles published between 20th December 2019 and 30th August 2020. We used 14 key words related to COVID 19 and Lung Cancer. The articles were selected by two senior clinicians who excluded overlapping information and prioritized original research reports and professional organization’s official recommendations. Results: There were 562 papers corresponding to the search criteria, of which 64 were analyzed. Treatment decision must be tailored according to the status of SARS CoV-2 positivity, the aim of the treatment (curative VS palliative), pathological type and clinical stage, disease complications, symptoms, prognostic, performance status, and alternative treatments. Hypofractionation is preferred whenever possible in order to minimize risk for patients and staff. Safety measures have to be implemented, with extra cautions if SARS CoV-2 positive patients have to be treated. Cone beam CT can be used early identification of lung infiltrates and special attention is recommended to differentiate Radiation pneumonitis from COVID-19 pneumonia. Journal of Medical and Radiation Oncology Journal homepage: www.jmedradonc.org Review 94 Conclusion: For SARS CoV-2 positive lung cancer patients the treatment should be postponed, until they are tested negative. For patients which are SARS CoV-2 negative treated with curative intent, hypofractionated schedules are preferred. Palliative treatments should be given according to the life threatening risk."

Trends in pneumonectomy for treatment of small-cell lung cancer

2020 ◽  
Vol 28 (9) ◽  
pp. 583-591
Author(s):  
Jasmine Zhao ◽  
Alexandra Nguyen ◽  
Li Ding ◽  
Elizabeth A David ◽  
Scott M Atay ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Clinical Stage ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Background According to practice guidelines, patients with clinical stage T1–2 node-negative small-cell lung cancer are candidates for surgical resection. However, the role of pneumonectomy in small-cell lung cancer patients is not well understood. The objective of this study was to assess the extent to which pneumonectomy is used and to evaluate the survival implications for small-cell lung cancer patients who underwent pneumonectomy. Methods A total of 106 small-cell lung cancer patients who underwent pneumonectomy between 2006 and 2016 and met the study criteria were identified in the National Cancer Database. Demographics and treatment regimens are described, and overall survival was assessed using Kaplan-Meier and log-rank tests. Results The most common treatment was surgery with adjuvant chemotherapy, followed by surgery only and surgery with neoadjuvant therapy. The 5-year overall survival for the entire cohort after pneumonectomy was 23%. In subgroup analysis, the 5-year overall survival was 30% for guideline-concordant clinical stage I patients and 28% for clinical stage II/III patients who underwent pneumonectomy. There was no statistical difference in survival according to pathologic N disease. Patients with a right-sided pneumonectomy had higher mortality than patients with a left-sided pneumonectomy. Conclusions This study suggests a role for pneumonectomy in clinical stage I and potentially some clinical stage II and III small-cell lung cancer patients. Right-sided pneumonectomy is associated with higher mortality and should be approached with caution. Despite declining trends over the past decades, pneumonectomy is still an effective treatment that is able to achieve acceptable survival outcomes.

Sign in / Sign up

Export Citation Format

Share Document